Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Electrophysiological features of SYT2 mutations; a novel and treatable neuromuscular syndrome

Electrophysiological features of SYT2 mutations; a novel and treatable neuromuscular syndrome

Thumbnail Image
Download
Name

JTroyLIttleton2.pdf

Size

370.28 KB

Format

Adobe PDF

Checksum (MD5)

8334fbd34154736289e575d8d75aa986

Author(s)
Whittaker, Roger G.
•
Herrmann, David N.
•
Bansagi, Boglarka
•
Hasan, Bashar Awwad Shiekh
•
Lofra, Robert Muni
•
Logigian, Eric L.
•
Sowden, Janet E.
•
Almodovar, Jorge L.
•
Zuchner, Stephan
•
Horvath, Rita
more
Alternative Title
Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome
Date Issued
December 2015
Journal
Neurology
Publisher
American Academy of Neurology (AAN)
Citation
Whittaker, Roger G., David N. Herrmann, Boglarka Bansagi, Bashar Awwad Shiekh Hasan, Robert Muni Lofra, Eric L. Logigian, Janet E. Sowden, et al. “ Electrophysiologic Features of SYT2 Mutations Causing a Treatable Neuromuscular Syndrome .” Neurology 85, no. 22 (December, 2015): 1964-1971.
Version
Author's final manuscript
Abstract
Objectives: To describe the clinical and electrophysiologic features of synaptotagmin II (SYT2) mutations, a novel neuromuscular syndrome characterized by foot deformities and fatigable ocular and lower limb weakness, and the response to modulators of acetylcholine release. Methods: We performed detailed clinical and neurophysiologic assessment in 2 multigenerational families with dominant SYT2 mutations (c.920T>G [p.Asp307Ala] and c.923G>A [p.Pro308Leu]). Serial clinical and electrophysiologic assessments were performed in members of one family treated first with pyridostigmine and then with 3,4-diaminopyridine. Results: Electrophysiologic testing revealed features indicative of a presynaptic deficit in neurotransmitter release with posttetanic potentiation lasting up to 60 minutes. Treatment with 3,4-diaminopyridine produced both a clinical benefit and an improvement in neuromuscular transmission. Conclusion: SYT2 mutations cause a novel and potentially treatable complex presynaptic congenital myasthenic syndrome characterized by motor neuropathy causing lower limb wasting and foot deformities, with reflex potentiation following exercise and a uniquely prolonged period of posttetanic potentiation.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/106562
DOI of Published Version
https://doi.org/10.1212/wnl.0000000000002185
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.